5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.
作者信息
Beck Alain, Reichert Janice M, Wurch Thierry
机构信息
Physico-Chemistry Department, Centre d’Immunologie Pierre Fabre, Saint Julien en Genevois, France.
出版信息
MAbs. 2010 Mar-Apr;2(2):108-28. doi: 10.4161/mabs.2.2.11302.
Abstract
摘要
相似文献
1
5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.
MAbs. 2010 Mar-Apr;2(2):108-28. doi: 10.4161/mabs.2.2.11302.
2
6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.
MAbs. 2011 Mar-Apr;3(2):111-32. doi: 10.4161/mabs.3.2.14788. Epub 2011 Mar 1.
3
8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland.
MAbs. 2013 May-Jun;5(3):339-57. doi: 10.4161/mabs.24105. Epub 2013 Mar 14.
4
4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland.
MAbs. 2009 Mar-Apr;1(2):93-103. doi: 10.4161/mabs.1.2.7890. Epub 2009 Mar 20.
5
9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland.
MAbs. 2014 Mar-Apr;6(2):309-26. doi: 10.4161/mabs.27903. Epub 2014 Jan 17.
6
7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.
MAbs. 2012 Mar-Apr;4(2):134-52. doi: 10.4161/mabs.4.2.19426. Epub 2012 Mar 1.
7
Monoclonal antibody therapeutics: history and future.
Curr Opin Pharmacol. 2012 Oct;12(5):615-22. doi: 10.1016/j.coph.2012.08.001. Epub 2012 Aug 21.
8
Therapeutic antibodies: magic bullets hit the target.
Nature. 2002 Jun 6;417(6889):584-6. doi: 10.1038/417584a.
9
Cancer immunotherapeutics: evolution of monoclonal antibodies to peptide immunogens.
Monoclon Antib Immunodiagn Immunother. 2014 Jun;33(3):179-82. doi: 10.1089/mab.2014.0021. Epub 2014 Jun 3.
10
Evolving trends in the treatment of low-risk myelodysplastic syndromes: immunomodulation and beyond--9th European Hematology Association Congress Geneva, Switzerland, 10-13 June 2004.
Transfus Med. 2007 Jun;17(3):151-60. doi: 10.1111/j.1365-3148.2006.00681.x.
引用本文的文献
1
Strategies for enriching and characterizing proteins with inhibitory properties on the yeast surface.
Protein Eng Des Sel. 2023 Jan 21;36. doi: 10.1093/protein/gzac017.
2
Production, characterization, and epitope mapping of monoclonal antibodies of ribosomal protein S3 (rpS3).
Anim Cells Syst (Seoul). 2021 Oct 6;25(5):323-336. doi: 10.1080/19768354.2021.1980100. eCollection 2021.
3
Antibody-drug conjugates: present and future.
MAbs. 2014 Jan-Feb;6(1):15-7. doi: 10.4161/mabs.27436.
4
Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621.
MAbs. 2012 Nov-Dec;4(6):710-23. doi: 10.4161/mabs.22160. Epub 2012 Sep 24.
5
Disulfide scrambling in IgG2 monoclonal antibodies: insights from molecular dynamics simulations.
Pharm Res. 2011 Dec;28(12):3128-44. doi: 10.1007/s11095-011-0503-9. Epub 2011 Jun 14.
6
6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.
MAbs. 2011 Mar-Apr;3(2):111-32. doi: 10.4161/mabs.3.2.14788. Epub 2011 Mar 1.
7
Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions.
Pharm Res. 2011 May;28(5):949-61. doi: 10.1007/s11095-011-0414-9. Epub 2011 Mar 25.
8
Biosimilar, biobetter and next generation therapeutic antibodies.
MAbs. 2011 Mar-Apr;3(2):107-10. doi: 10.4161/mabs.3.2.14785. Epub 2011 Mar 1.
9
Strategies and challenges for the next generation of therapeutic antibodies.
Nat Rev Immunol. 2010 May;10(5):345-52. doi: 10.1038/nri2747.
本文引用的文献
1
GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.
Expert Opin Drug Discov. 2010 Jan;5(1):95-111. doi: 10.1517/17460440903413504. Epub 2009 Dec 1.
2
Catumaxomab: clinical development and future directions.
MAbs. 2010 Mar-Apr;2(2):129-36. doi: 10.4161/mabs.2.2.11221.
3
Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.
MAbs. 2010 Jan-Feb;2(1):14-9. doi: 10.4161/mabs.2.1.10789. Epub 2010 Jan 30.
4
Development of biosimilars--pharmacokinetic and pharmacodynamic considerations.
J Biopharm Stat. 2010 Jan;20(1):46-61. doi: 10.1080/10543400903280357.
5
Patenting antibodies in Europe.
MAbs. 2009 Jul-Aug;1(4):385-6. doi: 10.4161/mabs.1.4.8802.
6
Ustekinumab.
MAbs. 2009 May-Jun;1(3):216-21. doi: 10.4161/mabs.1.3.8593.
7
Non-human primate immune libraries combined with germline humanization: an (almost) new, and powerful approach for the isolation of therapeutic antibodies.
MAbs. 2009 Jul-Aug;1(4):377-81. doi: 10.4161/mabs.1.4.8635. Epub 2009 Jul 5.
8
Guardians at the gate: patent protection for therapeutic monoclonal antibodies--part 1.
MAbs. 2009 Jul-Aug;1(4):382-4. doi: 10.4161/mabs.1.4.8860. Epub 2009 Jul 25.
9
European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK.
MAbs. 2009 Sep-Oct;1(5):394-416. doi: 10.4161/mabs.1.5.9630. Epub 2009 Sep 25.
10
Antibodies to watch in 2010.
MAbs. 2010 Jan-Feb;2(1):84-100. doi: 10.4161/mabs.2.1.10677. Epub 2010 Jan 16.
Zotero 插件